Drug Profile
Recombinant human bone morphogenetic protein 4 - StemGen
Alternative Names: BMP4 - StemGen; hBMP4 - StemGen; hrBMP4 - StemGen; HS 214; Recombinant Bone Morphogenic Protein-4Latest Information Update: 24 Oct 2023
Price :
$50
*
At a glance
- Originator StemGen
- Class Antineoplastics; Bone morphogenetic proteins; Calcium regulators; Recombinant proteins
- Mechanism of Action Bone morphogenetic protein receptor type I modulators; Bone morphogenetic protein receptor type II modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glioblastoma
- Suspended Colorectal cancer
Most Recent Events
- 14 Sep 2023 StemGen plans a phase II/III trial in Glioblastoma (Intratumoural) in 2024 (StemGen pipeline, September 2024)
- 28 Mar 2023 Phase I development is ongoing Netherlands (NCT02869243)
- 28 Mar 2023 StemGen plans a phase III trial for Glioblastoma (StemGen pipeline, March 2023)